Atovaquone

Atovaquone (Atavaquone) is a potent, selective and orally active inhibitor of the parasite’s mitochondrial cytochrome bc1 complex. Atovaquone is against human and P. falciparum cytochrome bc1 activity with IC50 values of 460 nM and 2.0 nM, respectively. Atovaquone is an antimalarial agent and has the potential for the investigation of neumocystis pneumonia, toxoplasmosis, malaria, and babesia[1][2].

Product Specifications

CAS Number

[95233-18-4]

Product Name Alternative

Atavaquone

UNSPSC

12352005

Hazard Statement

H302, H315, H319

Target

Antibiotic; Bacterial; Cytochrome P450; Parasite

Type

Reference compound

Related Pathways

Anti-infection; Metabolic Enzyme/Protease

Applications

COVID-19-immunoregulation

Field of Research

Infection; Cancer

Assay Protocol

https://www.medchemexpress.com/atovaquone.html

Purity

99.75

Solubility

DMSO : 8.33 mg/mL (ultrasonic)

Smiles

O=C1C([C@H]2CC[C@H](C3=CC=C(Cl)C=C3)CC2)=C(O)C(C4=C1C=CC=C4)=O

Molecular Formula

C22H19ClO3

Molecular Weight

366.84

Precautions

H302, H315, H319

References & Citations

[1]Nilsen A, et al. Quinolone-3-diarylethers: a new class of antimalarial drug.Sci Transl Med. 2013 Mar 20;5 (177) :177ra37.|[2]Schöler N, et al. Atovaquone nanosuspensions show excellent therapeutic effect in a new murine model of reactivated toxoplasmosis.Antimicrob Agents Chemother. 2001 Jun;45 (6) :1771-9.